FSHR and ovarian carcinoma: Although the "gonadotropin theory" of ovarian cancer pathogenesis remains a subject of controversy 14, 44, recent immunotherapies targeting FSHR have demonstrated high level of safety and efficacy in ovarian cancer treatment 11, 12.